Add time:08/30/2019         Source:sciencedirect.com

Rationale and objectivesDedicated contrast agents are now available for contrast-enhanced magnetic resonance angiography (CE-MRA). This study retrospectively compares the safety and diagnostic performance data from Phase III regulatory trials performed to evaluate GADOBENATE DIMEGLUMINE (cas 12700-20-8) (MultiHance®) and gadofosveset trisodium (Vasovist®) for renal and peripheral CE-MRA.

We also recommend Trading Suppliers and Manufacturers of GADOBENATE DIMEGLUMINE (cas 12700-20-8). Pls Click Website Link as below: cas 12700-20-8 suppliers